Since PPM1G participates in the activation of NF-κB programs and NF-κB is a critical tumor suppressor or oncogene (depending on the stimuli, cell-type, and context [78]), PPM1G also emerges as a critical target for diseases where NF-κB is constitutively activated (such as in chronic inflammatory disorders, skin cancers, and leukemias, among others). This evidence concerns the gene NFKB1 and leukemia.